NervGen Pharma Corp. (NGENF)
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General